Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Polycystic ovary syndrome (PCOS) is the most frequent endocrine-metabolic disorder among women at reproductive age. The diagnosis is based on the presence of at least two out of three criteria of the Rotterdam criteria (2003). In the last decades, the dysmetabolic aspect of insulin resistance and compensatory hyperinsulinemia have been taken into account as the additional key features in the etiopathology of PCOS, and they have been widely studied. Since PCOS is a complex and multifactorial syndrome with different clinical manifestations, it is difficult to find the gold standard treatment. Therefore, a great variety of integrative treatments have been reported to counteract insulin resistance. PCOS patients need a tailored therapeutic strategy, according to the patient's BMI, the presence or absence of familiar predisposition to diabetes, and the patient's desire to achieve pregnancy or not. The present review analyzes and discloses the main clinical insight of such complementary substances.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406066 | PMC |
| http://dx.doi.org/10.3390/biomedicines10081924 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome: A Randomized Clinical Trial.
JAMA
September 2025
Department of Obstetrics and Gynecology, Máxima Medical Center, Veldhoven, the Netherlands.
Importance: Pregnant individuals with polycystic ovary syndrome (PCOS) present with a higher risk of pregnancy complications, including gestational diabetes, preeclampsia, and preterm birth. Myo-inositol supplementation may reduce these risks.
Objective: To determine whether daily supplementation with myo-inositol during pregnancy among individuals with PCOS reduces the risk of a composite outcome of gestational diabetes, preeclampsia, and preterm birth.
To explore the relationship between endometrial hyperemia and polycystic ovary syndrome.
Open Life Sci
September 2025
School of Medicine, Shandong University, Jinan, Shandong, 250000, China.
The aim of this study is to investigate the characteristics and etiology of endometrial hyperemia in patients with polycystic ovary syndrome (PCOS) through two complementary approaches: clinical data analysis to characterize endometrial hyperemia and clinical trials to elucidate its underlying causes. ELISA was employed to quantify inflammatory mediators in endometrial tissue, while reverse transcription quantitative polymerase chain reaction (RT-qPCR) and Western blot analyses were conducted to assess the expression levels of molecules associated with endoplasmic reticulum stress (ERS). Additionally, RT-qPCR was used to determine the mRNA expression levels of HIF-1α, VEGF, and EPO.
View Article and Find Full Text PDFElevated level of platelet factor 4 in follicular fluid is associated with polycystic ovary syndrome.
Clin Biochem
September 2025
The Affiliated Taian City Central Hospital of Qingdao University, 271000 Taian, China. Electronic address:
Objective: This present study aimed to measure platelet factor 4 (PF4) protein level in follicular fluid of patients with polycystic ovary syndrome (PCOS) and analyzed the correlation between follicular PF4 level with clinical characteristics.
Methods: Sixty-seven women (36 PCOS patients vs. 31 non-PCOS women) were enrolled in the study.
Vascular imbalance in polycystic ovary syndrome: Insights into endothelial dysfunction.
PLoS One
September 2025
Department of Biostatistics, Faculty of Medicine, Malatya Turgut Özal University, Malatya, Turkey.
Polycystic ovary syndrome (PCOS) is a multifactorial endocrine disorder associated with vascular dysfunction and increased cardiovascular risk. This study aims to investigate the dysregulation of vascular tone in PCOS, focusing on the imbalance between vasodilators (nitric oxide [NO] and apelin) and vasoconstrictors (noradrenaline and reduced prostacyclin). By examining these factors, the study seeks to elucidate their contribution to endothelial dysfunction and cardiovascular complications in PCOS patients.
View Article and Find Full Text PDFLipid Accumulation Product Index as a Marker of Metabolic Syndrome in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.
Endocrinol Diabetes Metab
September 2025
Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Imam Khomeini Hospital, Tehran, Iran.
Background: Lipid accumulation product (LAP) index is a measure of lipid toxicity based on triglyceride and waist circumference. The aim of the current study is to explore the relationship between LAP index and metabolic syndrome (MetS) among women with polycystic ovary syndrome (PCOS) in a systematic review and meta-analysis.
Methods: Web of Science, Embase and PubMed online databases were systematically searched for studies investigating the relationship between LAP index and MetS in PCOS.